JUL 10, 2018 11:15 PM PDT

TdT Positive Cells - Not Just for Neoplasms

Terminal deoxyncleotidyl transferase (TdT) is a unique DNA polymerase molecule that is expressed by immature lymphoid cells, both normal and mutagenic.  As a cell ages, it loses the TdT expression capability.  Young lymph progenitor cells would be expected then to have this cell marker; cancerous lymph cells can be mutated versions of those young lymph progenitor cells growing out of control so increased TdT levels could be expected, and in fact have been used diagnostically in laboratory medicine.  TdT has been an identifiable marker since the late 1980s where it was found to be enhanced in acute undifferentiated leukemias, immature acute lymphoblastic leukemias, and in a fraction of cases of leukemic patients in blast crisis.  TdT acts by catalyzing the reaction that leads to the addition of deoxynucleotides to hydroxyl ends of oligonucleotides as part of DNA synthesis.  It also contributes to differences in antibody recognition sites by rearrangement of immunoglobulins or T-cell receptors.  It has long been associated with very undifferentiated neoplasms.

A new article published in the journal Human Pathology is a reminder that healthy lymph nodes and lymph cells can also express TdT because they are early lymphoid precursors; this is especially true in pediatric lymph nodes.  There are benign TdT positive lymph nodes in pediatric patients and this group focused on characterizing the presence of benign TdT positive cells and characterize the typical phenotype associated with their presence. 

Findings included that TdT was sparsely positive in all pediatric cases and in more than three quarters of adult lymph nodes evaluated (n=141).  It was noted that there was increased density of TdT positive cells in pediatric lymph nodes and TdT presence was not found to be associated with any clinical or histological factor other than identifying that these were lymphoid precursors with CD34 and CD10 also being expressed.

The study serves as a reminder to be mindful of the common phenotype of TdT positivity in early healthy lymphoid precursors and to carefully avoid misidentification of these cells as early neoplasm markers.

Sources: Human Pathology, International Journal of Biological Markers, American Journal of Clinical Pathology, Pathology Outlines,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUL 17, 2018
Health & Medicine
JUL 17, 2018
Can the Keto Diet Make Cancer Treatment More Effective?
It’s been said that “you are what you eat” but with so many diet plans and trends, it can be hard to choose. Paleo, keto, Mediterranean,...
JUL 26, 2018
Genetics & Genomics
JUL 26, 2018
When a Cancer Gene Switches Sides
All cells carry a gene named p53, which has a vital role in shielding the body from cancer. But it can betray cells too....
JUL 31, 2018
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
SEP 06, 2018
SEP 06, 2018
The Oncomicrobiome - Linking Microbes and Cancer
Scientists want to know more about how the microbes we carry in and on us are related to cancer development....
SEP 11, 2018
Cannabis Sciences
SEP 11, 2018
The Potential Anti-cancer Effects of Cannabinoids
They're known for helping to reduce the impact of cancer drug side effects, but it's possible that cannabinoids themselves are cancer fighters....
OCT 17, 2018
Cell & Molecular Biology
OCT 17, 2018
Saving Patients From Unnecessary Chemotherapy with a Blood Test
Often, cancer patients get chemotherapy after surgery to ensure that their cancer will not come back; for many it's not needed....
Loading Comments...